Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Correspondence on “SARS-CoV-2 vaccination in rituximab-treated patients: evidence for impaired humoral but inducible cellular immune response” by Bonelli et al
Caoilfhionn M Connolly, Darya Koenig, Srekar N. Ravi, et al.
Annals of the Rheumatic Diseases (2021) Vol. 80, Iss. 10, pp. e164-e164
Closed Access | Times Cited: 19

Showing 19 citing articles:

Immunological and clinical efficacy of COVID-19 vaccines in immunocompromised populations: a systematic review
Simon Galmiche, Liêm Binh Luong Nguyen, Éric Tartour, et al.
Clinical Microbiology and Infection (2021) Vol. 28, Iss. 2, pp. 163-177
Open Access | Times Cited: 180
A prospective multicenter study assessing humoral immunogenicity and safety of the mRNA SARS-CoV-2 vaccines in Greek patients with systemic autoimmune and autoinflammatory rheumatic diseases
Athanasios G. Tzioufas, Athanasios‐Dimitrios Bakasis, Andreas V. Goules, et al.
Journal of Autoimmunity (2021) Vol. 125, pp. 102743-102743
Open Access | Times Cited: 56
Perspective on COVID-19 vaccination in patients with immune-mediated kidney diseases: consensus statements from the ERA-IWG and EUVAS
Kate Stevens, Eleni Frangou, Jae Il Shin, et al.
Nephrology Dialysis Transplantation (2022) Vol. 37, Iss. 8, pp. 1400-1410
Open Access | Times Cited: 29
The COVID-19 pandemic and ANCA-associated vasculitis – reports from the EUVAS meeting and EUVAS education forum
Andreas Kronbichler, Duvuru Geetha, Rona Smith, et al.
Autoimmunity Reviews (2021) Vol. 20, Iss. 12, pp. 102986-102986
Open Access | Times Cited: 38
Predictors of Immunogenic Response to the BNT162b2 mRNA COVID-19 Vaccination in Patients with Autoimmune Inflammatory Rheumatic Diseases Treated with Rituximab
Victoria Furer, Tali Eviatar, Devy Zisman, et al.
Vaccines (2022) Vol. 10, Iss. 6, pp. 901-901
Open Access | Times Cited: 23
Immunogenicity of SARS-CoV-2 vaccination in rituximab-treated patients: Effect of timing and immunologic parameters
Daniel Magliulo, Stefanie D. Wade, Vasileios C. Kyttaris
Clinical Immunology (2021) Vol. 234, pp. 108897-108897
Open Access | Times Cited: 28
Optimal time for COVID-19 vaccination in rituximab-treated dermatologic patients
Chutima Seree-aphinan, Yanisa Ratanapokasatit, Poonkiat Suchonwanit, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 11
Immunogenicity, breakthrough infection, and underlying disease flare after SARS-CoV-2 vaccination among individuals with systemic autoimmune rheumatic diseases
Julie J. Paik, Jeffrey A. Sparks, Alfred H.J. Kim
Current Opinion in Pharmacology (2022) Vol. 65, pp. 102243-102243
Open Access | Times Cited: 19
Antibody Response to mRNA Vaccines against SARS-CoV-2 with Chronic Kidney Disease, Hemodialysis, and after Kidney Transplantation
Lukas Buchwinkler, Claire Anne Solagna, Janosch Messner, et al.
Journal of Clinical Medicine (2021) Vol. 11, Iss. 1, pp. 148-148
Open Access | Times Cited: 22
mRNA-1273 vaccine (Moderna): a better option than BNT162b2 (Pfizer) in kidney transplant recipients and dialysis patients?
Veerle Wijtvliet, Kevin K. Ariën, Steven Abrams, et al.
Nephrology Dialysis Transplantation (2021) Vol. 37, Iss. 4, pp. 799-803
Open Access | Times Cited: 17
COVID-19 mRNA Vaccine in Patients With Lymphoid Malignancy or Anti-CD20 Antibody Therapy: A Systematic Review and Meta-Analysis
Yusuke Ito, Akira Honda, Mineo Kurokawa
Clinical Lymphoma Myeloma & Leukemia (2022) Vol. 22, Iss. 8, pp. e691-e707
Open Access | Times Cited: 12
Response to: ‘Correspondence on ‘SARS-CoV-2 vaccination in rituximab-treated patients: evidence for impaired humoral but inducible cellular immune response’’ by Westhoff et al
Michael Bonelli, Daniel Aletaha
Annals of the Rheumatic Diseases (2021) Vol. 80, Iss. 10, pp. e163-e163
Closed Access | Times Cited: 14
Impact of rituximab on humoral response to COVID-19 booster vaccine and antibody kinetics in patients with anti–neutrophil cytoplasmic antibody vasculitis
Sam Kant, Duvuru Geetha
Kidney International (2021) Vol. 100, Iss. 5, pp. 1124-1127
Open Access | Times Cited: 13
The Risk of Severe Infections Following Rituximab Administration in Patients With Autoimmune Kidney Diseases: Austrian ABCDE Registry Analysis
Balazs Odler, Martin Windpessl, Marcell Krall, et al.
Frontiers in Immunology (2021) Vol. 12
Open Access | Times Cited: 12
SARS-CoV-2 Vaccine Response in Patients With Antineutrophil Cytoplasmic Autoantibody–Associated Vasculitis
Lauren Floyd, Mohamed Elsayed, Tobias Seibt, et al.
Kidney International Reports (2021) Vol. 7, Iss. 3, pp. 629-632
Open Access | Times Cited: 10
Response to: Correspondence on “SARS-CoV-2 vaccination in rituximab-treated patients: evidence for impaired humoral but inducible cellular immune response” by Bonelli et al
Michael Bonelli, Daniel Aletaha
Annals of the Rheumatic Diseases (2021) Vol. 80, Iss. 10, pp. e167-e167
Closed Access | Times Cited: 5
Der Einfluss von Immunsuppression und chronischen Nierenerkrankungen auf das Ansprechen auf COVID-19-Impfungen
Martin Windpessl, Gunnar H. Heine, Sören L. Becker, et al.
DMW - Deutsche Medizinische Wochenschrift (2021) Vol. 146, Iss. 19, pp. 1277-1282
Closed Access | Times Cited: 3
Cardiomyopathy following COVID-19 vaccination in a patient with systemic lupus erythematosus
Avreena Kaur Bhullar, Zhi Chee Chew, Ong Ping Seung, et al.
Modern Rheumatology Case Reports (2022) Vol. 7, Iss. 1, pp. 87-91
Open Access | Times Cited: 1
Humoral responses to SARS-CoV-2 vaccination in rituximab-treated patients depend on peripheral B cell re-population rather than the timings of the dosing
Padmanabha Shenoy, Rashwith Umesh, Aby Paul, et al.
Indian Journal of Rheumatology (2022) Vol. 17, Iss. 1, pp. 30-30
Closed Access
Page 1

Scroll to top